Abbvie announces acquisition of approval for chronic hepatitis C oral treatment VIEKIRAX/EXVIERA
Abbvie Korea(CEO Hong-Ki Yoo) announced the Korea Ministry of Health and Welfare approved VIEKIRAX(generic name: ombitasvir, paritaprevir, ritonavir) and EXVIERA(generic name: sasabuvir) as chronic hepatitis C treatment on the 17th. VIEKIRAX and EXVIERA acquired approval as the treatment of chron...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
